Gilead Sciences (GILD) : Forte Capital Adv reduced its stake in Gilead Sciences by 7.23% during the most recent quarter end. The investment management company now holds a total of 46,178 shares of Gilead Sciences which is valued at $3,373,765 after selling 3,600 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Gilead Sciences makes up approximately 1.31% of Forte Capital Adv’s portfolio.
Other Hedge Funds, Including , Hudson Valley Investment Advisors Inc Adv boosted its stake in GILD in the latest quarter, The investment management firm added 645 additional shares and now holds a total of 19,130 shares of Gilead Sciences which is valued at $1,444,124. Gilead Sciences makes up approx 0.45% of Hudson Valley Investment Advisors Inc Adv’s portfolio.Carroll Financial Associates boosted its stake in GILD in the latest quarter, The investment management firm added 365 additional shares and now holds a total of 5,240 shares of Gilead Sciences which is valued at $395,568. Gilead Sciences makes up approx 0.06% of Carroll Financial Associates’s portfolio. Founders Financial Securities added GILD to its portfolio by purchasing 10,679 company shares during the most recent quarter which is valued at $803,488. Gilead Sciences makes up approx 0.35% of Founders Financial Securities’s portfolio.Washington Trust Bank reduced its stake in GILD by selling 2,270 shares or 37.2% in the most recent quarter. The Hedge Fund company now holds 3,832 shares of GILD which is valued at $297,248. Gilead Sciences makes up approx 0.07% of Washington Trust Bank’s portfolio.
Gilead Sciences closed down -1.67 points or -2.21% at $73.82 with 1,19,09,999 shares getting traded on Tuesday. Post opening the session at $75.14, the shares hit an intraday low of $73.56 and an intraday high of $75.28 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by RBC Capital Mkts on Oct 3, 2016 to “Outperform” and Lowered the Price Target to $ 95 from a previous price target of $105 .Shares were Downgraded by Leerink Partners on Sep 27, 2016 to ” Mkt Perform” and Lowered the Price Target to $ 94 from a previous price target of $112 .Berenberg Initiated Gilead Sciences on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $112.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.